T Lymphocyte News and Research

RSS

Scientists develop new type of precise therapeutic vaccine against leukemia

Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

12 Oct 2020

Case report of arthritis in a COVID-19 patient

The current paper published in the The Lancet Rheumatology discusses arthritis in a 58-year-old white woman with COVID-19 of less than severe intensity.

7 Oct 2020

TCR's quantity and clonality are linked to prognosis of colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in the world, with more than one and a half million new cases diagnosed annually.

7 Oct 2020

Low lymphocyte count before COVID-19 heightens death risk

Researchers at the University of Rochester Medical Center have conducted a study suggesting that having a low white blood cell count (lymphocytopenia) prior to exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be associated with an increased risk of dying from coronavirus disease 2019 (COVID-19).

6 Oct 2020

Severe COVID-19 in pregnancy increases risk for adverse maternal and neonatal outcomes

A new study published in the American Journal of Obstetrics and Gynecology in September 2020 reports the impact of severe COVID-19 on pregnancy, making an important contribution to the management of the condition in this subgroup of patients.

5 Oct 2020

Sebum changes in COVID-19 patients, for future testing and prognosis

Now, a new study published on the preprint server medRxiv in September 2020 shows that sebum lipids change in COVID-19. This could help develop a cheap and straightforward method of non-invasive diagnosis.

5 Oct 2020

Lung tissue in fatal COVID-19 shows broad cell tropism and extensive damage

In a recent preprint paper published on the medRxiv server, researchers demonstrated their investigation of fatal COVID-19 patients to assess infection in various cell types and the extent of damage it caused to the lung tissues.

30 Sep 2020

Healthy vitamin D levels could reduce COVID-19 complications

Published in the journal PLOS ONE, the study investigates the link between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes and parameters of immune function and mortality due to COVID-19.

28 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020

Anti-N-protein IgG may predict severity of COVID-19

A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Sep 2020

Stroke patients with COVID-19 have increased systemic inflammation, higher mortality risk

Stroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according to University of Alabama at Birmingham research led by Chen Lin, M.D., an assistant professor in the UAB Department of Neurology.

19 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Underlying pathology of MIS-C in children following SARS-CoV-2 infection

Researchers at the Icahn School of Medicine at Mount Sinai, New York, have conducted a study that sheds light on the molecular underpinnings of multisystem inflammatory syndrome in children (MIS-C).

3 Sep 2020

Newly designed hydrogels allow the culture of T-cells for use in cancer immunotherapy

A team with the participation of researchers from the Spanish National Research Council has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

31 Aug 2020

Scientists describe known approaches for treatment of SARS-CoV-2 infection

Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.

29 Aug 2020

New diagnostic tool can predict cancer patients' response to immunotherapy

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

27 Aug 2020

Pfizer/BioNTech COVID-19 vaccine candidate BNT162b2 profiled for large scale clinical trials

Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.

23 Aug 2020